Drug development with Celltech's monoclonal antibodies and Access Pharmaceuticals' drug delivery technology

Access Pharmaceuticals, Inc. Announces Oral Drug Delivery Research Collaboration

15-Sep-2003
ACCESS PHARMACEUTICALS, INC. announced that it has entered into a research collaboration in oral drug delivery with the Celltech Group plc, of Slough, England. The goal of the collaboration is to develop oral drug delivery options for Celltech's monoclonal antibodies and antibody fragments using Access' proprietary vitamin B12 oral drug delivery technology. In preclinical studies, this technology has already demonstrated its potential to facilitate the absorption of proteins following oral administration. Currently, administration of therapeutic monoclonal antibodies and antibody fragments is possible only by parenteral methods. Specific financial terms of the collaboration have not been disclosed. Under the terms of the Agreement, Celltech has been granted rights to license the Access technology for a defined number of antigens. Both Access and Celltech retain ownership of their respective underlying oral drug delivery technology and monoclonal antibodies. The vitamin B12 oral drug delivery technology utilizes the body's natural transport system for vitamin B12. This receptor-mediated process actively transports vitamin B12 from the gut to the blood stream. Access' scientists have found that the attachment of vitamin B12 to drugs, polymers containing drugs, and even drugs encapsulated in nanoparticles provide formulations which are absorbed into the body using the vitamin B12 uptake mechanism. Commenting on the agreement, Kerry P. Gray, President and CEO of Access stated, "We are excited about the potential of this relationship with Celltech. Extensive preclinical work has been conducted evaluating the vitamin B12 oral drug delivery technology which has demonstrated the potential for this receptor-based oral transport delivery system. Utilizing the vitamin B12 system in combination with our nanoparticle technology offers the potential for the effective oral delivery of macromolecules including monoclonal antibodies."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous